Fesoterodine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Fesoterodine
Fesoterodine.svg
Space-filling model of the fesoterodine molecule
Clinical data
Trade names Toviaz
AHFS/Drugs.com Monograph
MedlinePlus a609021
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 52% (active metabolite)
Protein binding 50% (active metabolite)
Metabolism Hepatic (CYP2D6- and 3A4-mediated)
Elimination half-life 7–8 hours (active metabolite)
Excretion Renal (70%) and fecal (7%)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.167.339 Edit this at Wikidata
Chemical and physical data
Formula C26H37NO3
Molar mass 411.278 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[1] It was approved by the European Medicines Agency in April 2007,[2] the US Food and Drug Administration on October 31, 2008 [3] and Health Canada on February 9, 2012.[4]

Fesoterodine is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.

Efficacy[edit]

Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists.[5] Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.[5]

References[edit]